Contrasting Geron (NASDAQ:GERN) & Evoke Pharma (NASDAQ:EVOK)

Geron (NASDAQ:GERNGet Free Report) and Evoke Pharma (NASDAQ:EVOKGet Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Volatility and Risk

Geron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.

Profitability

This table compares Geron and Evoke Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Geron -682.48% -67.53% -45.46%
Evoke Pharma -71.32% -308.49% -53.66%

Insider and Institutional Ownership

73.7% of Geron shares are held by institutional investors. 3.1% of Geron shares are held by insiders. Comparatively, 6.1% of Evoke Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Geron and Evoke Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron 0 1 8 2 3.09
Evoke Pharma 0 0 0 0 0.00

Geron presently has a consensus price target of $7.15, suggesting a potential upside of 104.87%. Given Geron’s stronger consensus rating and higher probable upside, equities analysts plainly believe Geron is more favorable than Evoke Pharma.

Earnings and Valuation

This table compares Geron and Evoke Pharma”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Geron $29.48 million 71.56 -$184.13 million ($0.32) -10.91
Evoke Pharma $8.62 million 0.87 -$7.79 million ($10.99) -0.46

Evoke Pharma has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Geron beats Evoke Pharma on 11 of the 15 factors compared between the two stocks.

About Geron

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.